早期系统性硬化症中免疫抑制药物与预防损伤累积
这项回顾性研究纳入病程两年以内的加拿大和澳大利亚系统性硬化症患者,分别观察局限皮肤型与弥漫皮肤型患者中曾暴露或从未暴露于免疫抑制药物者的全球器官损伤累积情况,以硬皮病临床试验联盟损伤指数为结局,采用逆概率治疗加权平衡组间并拟合边缘结构广义估计方程模型。
要点
- 局限皮肤型队列210例中34%曾暴露于免疫抑制药物,暴露与较低的损伤评分相关。
- 弥漫皮肤型队列192例中76%曾暴露于免疫抑制药物,暴露与损伤评分无关联。
- 作者认为局限皮肤型中免疫抑制药物对损伤累积有保护作用,弥漫皮肤型中未能确定该效应。
核心结论
- 在这项采用逆概率治疗加权校正混杂因素的回顾性观察性队列研究中,局限皮肤型系统性硬化症患者接受免疫抑制药物对损伤累积具有保护作用。
- 弥漫皮肤型系统性硬化症患者中未能确定该效应,但可能存在未知混杂因素,作者建议弥漫皮肤型患者接受免疫抑制药物的前瞻性研究应纳入硬皮病临床试验联盟损伤指数以确定免疫抑制药物对损伤累积的可能效应。
研究设计与样本
- 回顾性研究,纳入加拿大和澳大利亚队列中病程两年及以内的系统性硬化症患者。
- 局限皮肤型系统性硬化症与弥漫皮肤型系统性硬化症患者分别观察,并分为曾暴露于免疫抑制药物组与从未暴露于免疫抑制药物组。
- 结局为硬皮病临床试验联盟损伤指数,采用逆概率治疗加权平衡研究组并拟合边缘结构广义估计方程模型。
主要发现
- 局限皮肤型系统性硬化症队列有210例患者,其中34%曾暴露于免疫抑制药物。
- 局限皮肤型系统性硬化症中,暴露于免疫抑制药物与较低的损伤评分相关。
- 弥漫皮肤型系统性硬化症队列有192例患者,其中76%曾暴露于免疫抑制药物。
- 弥漫皮肤型系统性硬化症中,暴露于免疫抑制药物与损伤评分无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文为回顾性观察性队列研究。
- 弥漫皮肤型系统性硬化症中可能存在未知混杂因素。
- 作者建议对接受免疫抑制药物的弥漫皮肤型系统性硬化症患者开展前瞻性研究,并纳入硬皮病临床试验联盟损伤指数以确定免疫抑制药物对损伤累积的可能效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Organ damage in patients with systemic sclerosis (SSc) in individual organs such as the lungs may be prevented by receiving immunosuppressive drugs (ISs). A new measure of global organ damage, the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI), has allowed us to investigate whether receiving ISs may reduce global organ damage accrual in patients with early SSc. METHODS: This was a retrospective study of patients with two or less years of disease duration in Canadian and Australian cohorts with SSc. Patients with either limited cutaneous SSc (lcSSc) or diffuse cutaneous SSc (dcSSc) were observed separately and divided into groups who were either ever or never exposed to ISs. The SCTC-DI was the outcome, and inverse probability of treatment weighting (IPTW) was used to balance the study groups and to fit a marginal structural generalized estimating equation model. RESULTS: In the cohort with lcSSc, there were 210 patients, of whom 34% were exposed to ISs at some time. Exposure to ISs was associated with lower damage scores. In the cohort with dcSSc, there were 192 patients, of whom 76% were exposed to ISs at some time. Exposure to ISs was not associated with damage scores. CONCLUSION: In this retrospective observational cohort study, using IPTW to adjust for confounders, we found a protective effect of receiving ISs on damage accrual in patients with lcSSc. We were unable to determine such an effect in patients with dcSSc, but unknown confounders may have been present, and prospective studies of patients with dcSSc receiving ISs should include the SCTC-DI to determine the possible effect of ISs on damage accrual.
引用
- Baron M, Nikpour M, Hansen D, et al. Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual. Arthritis Care Res (Hoboken). 2025. PMID: 39542833. doi:10.1002/acr.25467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。